Traws Pharma (TRAW) Income from Non-Controlling Interests (2013 - 2018)
Traws Pharma (TRAW) posted quarterly Income from Non-Controlling Interests of $326000.0 for Q3 2018, up 300.0% quarter-over-quarter from -$163000.0 in Q2 2018.
Traws Pharma (TRAW) Income from Non-Controlling Interests (2013 - 2018) Analysis & Trends
Traws Pharma (TRAW) has reported Income from Non-Controlling Interests for 4 consecutive years, with $326000.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Income from Non-Controlling Interests changed N/A year-over-year to $326000.0; the TTM figure through Dec 2018 stood at $163000.0 (changed N/A YoY), while the FY2018 annual figure was $163000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests rose to $326000.0 in Q3 2018 per TRAW's latest filing, from -$163000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $326000.0 in Q3 2018 and bottomed at -$163000.0 in Q2 2018.
- Historically, Income from Non-Controlling Interests has averaged $750.0 across 3 years, with a median of -$25500.0 in 2014.
- Annual changes were most pronounced in 2014 — Income from Non-Controlling Interests tumbled 53.85% — and 2015, when it surged 35.14%.
- Traws Pharma's Income from Non-Controlling Interests stood at -$20000.0 in 2014, then changed by 0.0% to -$20000.0 in 2015, then surged by 1730.0% to $326000.0 in 2018.
- Business Quant data shows TRAW's Income from Non-Controlling Interests at $326000.0 in Q3 2018, -$163000.0 in Q2 2018, and -$20000.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 326,000.00 |
| Jun 30, 2018 | -163,000.00 |
| Jun 30, 2015 | -20,000.00 |
| Mar 31, 2015 | -24,000.00 |
| Dec 31, 2014 | -20,000.00 |
| Sep 30, 2014 | -29,000.00 |
| Jun 30, 2014 | -27,000.00 |
| Mar 31, 2014 | -37,000.00 |
| Dec 31, 2013 | -13,000.00 |